SyhinStas/iStock via Getty Images EU officials on June 11 will sign a contract with CSL Seqirus ( OTCQX:CSLLY ) to provide more than 40M doses of a prophylactic avian flu vaccine. The first shipments will go to Finland, Reuters reported . Terms call for 665,000 doses initially, with up to 40M more over four years.
As of early June, there are no active cases of bird flu in humans or animals, according to the European Centre for Disease Prevention and Control. Several bird flu cases have been found in the U.S.
The U.S. vaccine stockpile against bird flu currently consists of traditionally developed vaccines from GSK ( GSK ), Sanofi ( SNY ) and CSL.
Messenger-RNA-based vaccine makers Moderna ( MRNA ), Pfizer ( PFE ), and CureVac ( CVAC )/GSK are developing new shots. More on CSL, bird flu Bird flu death in Mexico linked to strain not seen in humans before Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Dividend scorecard for CSL.
